CLASS II Drug recall · Reported 15 Oct 2025 · FDA Enforcement Report
Bevacizumab 1.75 mg/ - syringe, Intravitreal Total Volume recalled
RC Outsourcing is recalling Bevacizumab 1.75 mg/ - syringe, Intravitreal Total Volume, distributed nationwide in the US. The recall was initiated on 22 Sep 2025 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0003-2026
- FDA event ID
- 97653
- Recalling firm
- RC Outsourcing, Lowellville, OH
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- 22 Sep 2025
- FDA classified
- 6 Oct 2025
- Reported
- 15 Oct 2025
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Sterility
Timeline
| 22 Sep 2025 | Recall initiated by company | |
| 6 Oct 2025 | Classified by FDA | +14 days |
| 15 Oct 2025 | Published in enforcement report | +9 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Lack of assurance of sterility.
A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.
Product as listed by the FDA
Bevacizumab 1.75 mg/0.07 mL - 0.25 mL syringe, Intravitreal, 0.07 mL Total Volume, Rx Only, Hospital/Office Use Only, Refrigerate, RC Outsourcing LLC, Lowellville, OH 44436.
Where it was distributed
Nationwide in the US
Questions about this recall
Why was it recalled?
Lack of assurance of sterility.
Which lots are affected?
Lot # 20250708-768A26, BUD: Oct 06, 2025 20250715-944DF2 BUD: Oct 13, 2025 20250722-55C603 BUD: Oct 20, 2025 20250722-5DC113 BUD: Oct 20, 2025
Where was it sold?
Nationwide in the US
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
Other Bevacizumab recalls
All 16| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Bevacizumab 1.25 MG/ Solution for Injection syringes recalled | Pine Pharmaceuticals | Sterility | Nationwide |
| Drug | CLASS III | Bevacizumab 2.5 mg/, Solution for Injection recalled | Pine Pharmaceuticals | Packaging Defects | Nationwide |
| Drug | CLASS II | Bevacizumab, 1.25 mg/ MJ Syringe Intravitreal Injection recalled | Pacifico National | Sterility | PR |
| Drug | CLASS II | Bevacizumab, 2.5 mg/, Norm-Ject Syringe Intravitreal recalled | Pacifico National | Sterility | PR |
| Drug | CLASS II | Bevacizumab 784 MG / Ns Ivpb recalled by Infusion Options | Infusion Options | Sterility | NY |